Collaborative CRISPR‐Cas System‐Enabled Detection of Circulating Circular RNA for Reliable Monitoring of Acute Myocardial Infarction

Acute myocardial infarction (AMI) is one of the major causes of death worldwide, posing significant global health challenges. Circular RNA (circRNA) has recently emerged as a potential diagnostic biomarker for AMI, providing valuable information for timely medical care. In this work, a new electrochemical method for circRNA detection by engineering a collaborative CRISPR‐Cas system is developed. This system integrates the unique circRNA‐targeting ability with cascade trans‐cleavage activities of Cas effectors, using an isothermal primer exchange reaction as the bridge. Using cZNF292, a circulating circRNA biomarker for AMI is identified by this group; as a model, the collaborative CRISPR‐Cas system‐based method exhibits excellent accuracy and sensitivity with a low detection limit of 2.13 × 10−15 m. Moreover, the method demonstrates a good diagnostic performance for AMI when analyzing whole blood samples. Therefore, the method may provide new insight into the detection of circRNA biomarkers and is expected to have great potential in AMI diagnosis in the future. A collaborative CRISPR/Cas system‐based electrochemical method is fabricated for detecting circRNA to achieve the accurate diagnosis of acute myocardial infarction. This method not only allows the highly sensitive and excellent specific detection of target circRNA, but also exhibits desirable application performance in whole blood samples.